Effect of Hemoglobin levels on Non-Invasive Blood Glucose Measurement in Type 2 Diabetes Patients
Article Sidebar
Main Article Content
Abstract
Objective: The study evaluated the effect of hemoglobin levels on non-invasive blood glucose measurement.
Method: Retrospective study in Type 2 diabetic patient, who were treated at Vajira Hospital from October 2018 to January 2019, were collected including baseline characteristic data and laboratory data from Ephis program. The data will be analyzed to determine the effect of hemoglobin levels on non-invasive blood glucose beasurement.
Result: A total of 200 type 2 diabetic patients were enrolled in the study. The average hemoglobin was 10.29±2.09 g/dL. The sample group with anemia accounted for 67%. The average glucose measured by non-invasive blood glucose meter was 109.57±31.38 mg/dL, by venous blood glucose was 154.37±57.27 mg/dL with statistically significant differences (p<0.001). The absolute relative difference values of the glucose measured by non invasive blood glucose meter and venous blood glucose was 29.95±21.45 mg/dL. The result of study on effect of hemoglobin levels on non-invasive blood glucose measurement in type 2 diabetic patients with or without anemia were no significant differences in the absolute relative difference values of the glucose measured by non-invasive blood glucose meter and venous blood glucose (p=0.425). The analysis of subgroups with anemia was classified by severity into mild, moderate, severe, and very severe. There was no difference in the absolute relative difference values of the glucose measured by the non-invasive blood glucose meter between subgroups (p=0.266, 0.852, 0.335 and 0.493, respectively).
Conclusion: The hemoglobin levels do not affect on the non-invasive blood glucose measurement in type 2 diabetic patients with or without anemia.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87(1):4-14.
Thailand Association of Diabetes. Diabetes situation in Western Pacific [internet]. 2008 [2020 October 3]. Available from: https://www.dmthai.org/new/index.php/sara-khwam-ru/the-chart/the-chart-1/2018-02-08-14-52-46
Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977-86.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):854-65.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837-53.
Heinemann L, Koschinsky T. Continuous glucose monitoring: an overview of today's technologies and their clinical applications. Int J Clin Pract Suppl 2002;(129):75-9.
Maruo K, Tsurugi M, Tamura M, Ozaki Y. In vivo noninvasive measurement of blood glucose by near-infrared diffuse-reflectance spectroscopy. Appl Spectrosc 2003;57(10):1236-44.
Abidin MTBZ, Rosli MKR, Shamsuddin SA, Madzhi NK, Abdullah MF. Initial quantitative comparison of 940nm and 950nm infrared sensor performance for measuring glucose non-invasively. IEEE International Conference on Smart Instrumentation, Measurement and Applications 2013;10:1-11.
Tura A, Maran A, Pacini G. Non-invasive glucose monitoring: assessment of technologies and devices according to quantitative criteria. Diabetes Res Clin Pract 2007;77(1):16-40.
Padalkar MV, Pleshko N. Wavelength-dependent penetration depth of near infrared radiation into cartilage. Analyst 2015;140(7):2093-100.
Lin T, Mayzel Y, Bahartan K. The accuracy of a non-invasive glucose monitoring device does not depend on clinical characteristics of people with type 2 diabetes mellitus. J Drug Assess 2018;7(1):1-7.
Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. New Jersey: Lawrence Erlbaum Associates; 1988.
Bahartan K, Horman K, Gal A, Drexler A, Mayzel Y, Lin T. Assessing the performance of a noninvasive glucose monitor in people with type 2 diabetes with different demographic profiles. J Diabetes Res 2017;17:1-8.